Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Guo, Zhiqiang ^a   Wang, Haolin ^b   Meng, Fandong ^a   Li, Jie ^a   Zhang, Shulan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; LYMPHOCYTE ANTIBODY; PROGRAMMED DEATH 1 ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; TRABECTEDIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; 1,3 DIOXOLANE DERIVATIVE; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; TETRAHYDROISOQUINOLINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; EFFECTOR CELL; FEMALE; GENE EXPRESSION; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PERITONEAL CAVITY; PROTEIN EXPRESSION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CYTOTOXICITY; DISEASE MODEL; DRUG EFFECTS; DRUG POTENTIATION; IMMUNIZATION; IMMUNOLOGY; OVARIAN NEOPLASMS; PERITONEUM LAVAGE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DIOXOLES; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FEMALE; IMMUNIZATION; IMMUNOSUPPRESSION; INTERFERON-GAMMA; MICE, INBRED C57BL; OVARIAN NEOPLASMS; PERITONEAL LAVAGE; PROGRAMMED CELL DEATH 1 RECEPTOR; TETRAHYDROISOQUINOLINES; TUMOR MICROENVIRONMENT;

EID: 84937829481     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0613-y     Document Type: Article

References (47)

1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T et al (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62:220-241
2. Bast RC Jr, Hennessy B, Mills GB (2009) The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9:415-428
3. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E et al (2004) Cancer statistics, 2004. CA Cancer J Clin 54:8-29
4. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:3194-3200
5. Kandalaft LE, Powell DJ Jr, Singh N, Coukos G (2011) Immunotherapy for ovarian cancer: what's next? J Clin Oncol 29:925-933
6. Ramakrishna V, Ross MM, Petersson M, Gatlin CC, Lyons CE, Miller CL et al (2003) Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. Int Immunol 15:751-763
7. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman JJ, Smith CV et al (2001) Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer. Gynecol Obstet Invest 51:254-261
8. Schondorf T, Engel H, Kurbacher CM, Brenne U, Kolhagen H, Gohring UJ et al (1998) Immunologic features of tumor-infiltrating lymphocytes and peripheral blood lymphocytes in ovarian cancer patients. J Soc Gynecol Investig 5:102-107
9. Wei H, Liu P, Swisher E, Yip YY, Tse JH, Agnew K et al (2012) Silencing of the TGF-beta1 gene increases the immunogenicity of cells from human ovarian carcinoma. J Immunother 35:267-275
10. Vermeij R, Leffers N, Melief CJ, Daemen T, Nijman HW (2012) Antigen-specific immunotherapy in ovarian cancer and p53 as tumor antigen. Curr Pharm Des 18:3804-3811
11. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G et al (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348:203-213
12. Cubillos-Ruiz JR, Engle X, Scarlett UK, Martinez D, Barber A, Elgueta R et al (2009) Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest 119:2231-2244
13. Mantia-Smaldone GM, Corr B, Chu CS (2012) Immunotherapy in ovarian cancer. Hum Vaccin Immunother 8:1179-1191
14. Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol 33:1974-1982
15. Shin DS, Ribas A (2015) The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr Opin Immunol 33C:23-35
16. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-2465
17. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454
18. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563-567
19. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C et al (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:558-562
20. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320-330
21. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N et al (2014) Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 15:69-77
22. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A et al (2008) Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 105:3005-3010
23. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV et al (2003) Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100:4712-4717
24. Wang DH, Guo L, Wu XH (2015) Checkpoint inhibitors in immunotherapy of ovarian cancer. Tumour Biol 36:33-39
25. Guo Z, Wang X, Cheng D, Xia Z, Luan M, Zhang S (2014) PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. PLoS One 9:e89350
26. Guo Z, Cheng D, Xia Z, Luan M, Wu L, Wang G et al (2013) Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer. J Transl Med 11:215
27. Lu L, Xu X, Zhang B, Zhang R, Ji H, Wang X (2014) Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. J Transl Med 12:36
28. Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G (2013) Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 73:3591-3603
29. Wei H, Zhao L, Li W, Fan K, Qian W, Hou S et al (2013) Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin. PLoS One 8:e84927
30. D'Incalci M, Galmarini CM (2010) A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 9:2157-2163
31. Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM et al (2010) Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol 28:3107-3114
32. Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM et al (2012) Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Eur J Cancer 48:2361-2368
33. Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M et al (2013) Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 23:249-262
34. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL et al (2012) Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4:127ra137
35. Wefers C, Lambert LJ, Torensma R, Hato SV (2015) Cellular immunotherapy in ovarian cancer: targeting the stem of recurrence. Gynecol Oncol 137:335-342
36. Zamarin D, Postow MA (2015) Immune checkpoint modulation: rational design of combination strategies. Pharmacol Ther 150:23-32
37. Melero I, Hirschhorn-Cymerman D, Morales-Kastresana A, Sanmamed MF, Wolchok JD (2013) Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res 19:1044-1053
38. Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G et al (2015) Safety and survival With GVAX pancreas prime and listeria monocytogenes-expressing Mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol 33:1325-1333
39. Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B et al (2008) Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res 14:1455-1463
40. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ et al (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124-128
41. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A et al (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371:2189-2199
42. Bevan MJ (2004) Helping the CD8(+) T-cell response. Nat Rev Immunol 4:595-602
43. Cheroutre H, Husain MM (2013) CD4 CTL: living up to the challenge. Semin Immunol 25:273-281
44. Zhang P, Su DM, Liang M, Fu J (2008) Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. Mol Immunol 45:1470-1476
45. Qin X, Liu C, Zhou Y, Wang G (2010) Cisplatin induces programmed death-1-ligand 1(PD-L1) over-expression in hepatoma H22 cells via Erk/MAPK signaling pathway. Cell Mol Biol (Noisy-le-grand) 56(Suppl):OL1366-1372
46. Noh H, Hu J, Wang X, Xia X, Satelli A, Li S (2015) Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells. Cell Commun Signal 13:14
47. Kanda SKG, Shiraishi H, Kubo E, Tanaka A, Utsumi H, Sunami KS et al (2014) Phase I study of anti-PD-1 antibody ONO-4538 and chemotherapy in patients with advanced non-small-cell lung cancer. Ann Oncol 25 (suppl_4):426-470. doi: 10.1093/annonc/mdu349